Thoracic endografting in a patient with hereditary hemorrhagic telangiectasia presenting with a descending thoracic aneurysm  by Andersen, Nicholas D. et al.
Thoracic endografting in a patient with hereditary
hemorrhagic telangiectasia presenting with a
descending thoracic aneurysm
Nicholas D. Andersen, MD,a John Dubose, BS,b Ankoor Shah, MD,b Teng Lee, MD,a
Stephanie B. Wechsler, MD,b and G. Chad Hughes, MD,a Durham, NC
A 53-year-old woman with no classic risk factors for aneurysm disease presented with the sudden onset of chest pain and
dyspnea. A large descending thoracic aortic aneurysm with focal type B dissection was identified and excluded by
emergency thoracic endografting. Further postoperative evaluation revealed a history of epistaxis, perioral telangiectasias,
hepatic hypervascularity, and a mutation in the gene expressing activin receptor-like kinase 1 (ALK1), leading to a
diagnosis of hereditary hemorrhagic telangiectasia. Aortic aneurysms associated with hereditary hemorrhagic telangiec-
tasia are extremely rare, and to our knowledge, this is the first report of thoracic endografting in this patient population.
(J Vasc Surg 2010;51:468-70.)Hereditary hemorrhagic telangiectasia (HHT), also
known as Osler-Weber-Rendu disease, is a rare autosomal-
dominant vascular angiodysplasia characterized by the de-
velopment of abnormal capillaries susceptible to trauma
and rupture.1 The most frequent manifestation is severe
recurrent epistaxis, often requiring advanced otorhinolar-
yngology management. Other manifestations include tel-
angiectasias and arteriovenous malformations (AVM) of
the skin, gastrointestinal tract, lung, liver, and central ner-
vous system.2 Large vessel aneurysms are rare, but have
been reported in the aorta, iliac, coronary, splenic, and
hepatic arteries.3-5 We describe thoracic endografting of a
symptomatic descending thoracic aortic aneurysm in a pa-
tient with previously undiagnosed HHT.
CASE REPORT
A 53-year-old woman presented to another hospital with the
sudden onset of midsternal chest pain and dyspnea. Her history
was notable only for osteopenia. She had no history of hyperten-
sion, tobacco use, or family members with aortic aneurysm disease.
An electrocardiogram and analysis of cardiac markers showed no
evidence of ischemia. Computed tomography (CT) angiography
of the chest revealed a 7.0-cm descending thoracic aortic aneurysm
with focal type B dissection within the aneurysm (Fig, A and C).
She was subsequently transferred to our center for aortic surgery.
The patient’s blood pressure at arrival was 125/79 mm Hg off
all vasoactive agents, and her oxygen saturation was 98% on 2 L of
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468oxygen. She continued to complain of chest pain. On physical
examination she was neurologically intact, without evidence of
malperfusion. She had small telangiectasias near the borders of her
lips but had no evidence of ectopia lentis, pectus excavatum,
arachnodactyly, hypermobile joints, scoliosis, or stretchy skin.
The patient underwent thoracic endografting using three
Gore TAG endoprostheses (W.L. Gore and Associates, Flagstaff,
Ariz) with intentional left subclavian artery coverage through an
open left femoral artery access (Fig, B and D).6 The operation was
completed 30 hours after the initial onset of symptoms and 18
hours after admission to our hospital. The patient was discharged 2
days later after an uneventful postoperative course. Follow-up CT
scans at 1, 3, and 9 months have demonstrated no endoleak or
stent-related problems and significant reverse remodeling of the
thoracic aorta.
Before discharge, the patient was evaluated by the rheumatol-
ogy and cardiovascular genetics services. Further questioning re-
vealed a history of frequent nosebleeds and many first-degree
relatives with cerebrovascular accidents. The patient’s father and
paternal uncle both had recurrent nosebleeds and telangiectasias
and had been told they likely had HHT. The patient had had a
prior brain magnetic resonance imaging (MRI) scan that showed
no evidence of AVMs. Postoperative chest, abdomen, and pelvis
CT imaging showed no pulmonary AVMs, but did reveal marked
hepatic artery hypertrophy with hypervascularity of the liver, con-
sistent with liver involvement in HHT.7 The patient had a normal
erythrocyte sedimentation rate and no other systemic signs or
symptoms of vasculitis. Given these findings, HHT was felt to be
the unifying diagnosis. Subsequent genetic testing revealed the
patient was heterozygous for a missense mutation in exon 8 of the
ALK1 gene, a mutation previously reported in the HHT mutation
database (www.hhtmutation.org).
DISCUSSION
We describe the unique case of an acutely symptomatic
descending thoracic aortic aneurysm of unknown etiology
leading to the identification of HHT in an otherwise
healthy middle-aged woman. HHT can be diagnosed by
satisfying three of the four following Curacao criteria estab-
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dation International: recurrent epistaxis, characteristic tel-
angiectasias, visceral lesions, and a first-degree relative with
HHT.2 More recently, mutations in endoglin (ENG) and
ALK1, two gene products involved in the transforming
growth factor- (TGF-) signaling pathway, have been
shown to cause HHT.8 DNA sequencing reveals mutations
in these two loci in 70% to 80% of patients with HHT.9 Our
patient fulfills all four Curacao criteria and harbors a char-
acteristic mutation in ALK1, making a definitive diagnosis
of HHT. Given the rarity of aortic involvement in HHT, it
remains possible that a second underlying disorder led to
aneurysm formation in this patient. HHT is the most likely
contributor, however, given that she demonstrated no ev-
idence of other connective tissue disease and aortic aneu-
rysms in HHT have been reported.
HHT is characterized by telangiectasias and AVMs
occurring throughout the body. Recent identification of
the molecular lesions causing HHT has elucidated the
TGF- signaling pathway in endothelial cells as the site of
dysfunction. ENG, ALK1, and other implicated genes are
downstream mediators of TGF- signaling, and mutations
compromise angiogenesis by leading to decreased endothe-
lial cell proliferation and migration. Cytoskeletal fragility
caused by disruption of actin polymerization is also ob-
Fig. (A, B) Cross-sectional and (C, D) three-dimension
TeraRecon Inc, San Mateo, Calif) of the aorta (A, C) bef
thoracic aortic aneurysm exclusion.served.8 The end result is an unstable capillary networkcharacterized by dilated postcapillary venules and prone to
the development of AVMs in both large and small vessels.1
The pathogenesis of large vessel aneurysms in HHT
remains poorly characterized owing to the low rate of
occurrence. However, the restriction of large vessel disease
to discrete lesions has led to the hypothesis that an inciting
event is necessary for the formation of a vascular lesion.1
Aortic aneurysm specimens have been described from two
patients with HHT, without the identification of a unifying
histologic pattern. One specimen demonstrated severe ath-
erosclerosis with slight lymphocytic infiltration,5 and the
other demonstrated patchy disruption of the elastic lamellar
pattern of the media.3 Both samples lacked cystic medical
necrosis, suggesting a pathogenetic mechanism distinct
from connective tissue disease. These observations could
suggest aneurysms in HHT are triggered by a routine
inciting event, such as atherosclerosis, leading to acceler-
ated aneurysm growth and degeneration in vessel walls
inherently prone to dilation and fragility.
This is the first report to our knowledge of an aortic
aneurysm in a patient with HHT in the endovascular era,
and previously described cases were repaired using tradi-
tional open surgery.3,5,10,11 Emergency endografting is
generally accepted for the treatment of symptomatic tho-
racic aneurysms or acute dissection where the risk of rup-
puted tomography reconstruction (TeraRecon system,
d (B, D) after repair demonstrate successful descendingal com
ore anture is imminent, even in young low-risk patients where
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geons avoid the use of endografts in patients with connec-
tive tissue disease where the entire aorta is compromised,
such as Marfan or Loeys-Dietz syndrome, due to young
patient age and concerns of deploying the device into
diseased landing zones where the risk of late endoleak due
to disease progression may be higher.12
HHT appears unique from connective tissue disease
given that vascular lesions typically occur at discrete loca-
tions.13 Nonetheless, areas of uninvolved aorta in HHT
likely remain susceptible to future inciting events, and case
reports have described HHT patients with multiple large
vessel aneurysms,3-5 suggesting some heightened large ves-
sel instability in certain patients with HHT. The choice of
endografting vs open surgery for aneurysm repair in a
patient with known HHT will likely require careful case-
by-case evaluation. However, it seems prudent that open
surgery would be considered in the elective setting given
the possibility of disease recurrence in endograft landing
zone areas. In the emergency setting, the use of thoracic
endografts has been proposed, even in patients with con-
nective tissue disease, given the low procedural morbidity
and mortality, and the same could certainly be considered
for HHT patients requiring emergency repair.14
CONCLUSION
We present a case of emergency thoracic endografting
in a patient later diagnosed with HHT. HHT should be
included in the differential diagnosis of aortic aneurysms of
unclear etiology. Large vessel aneurysm disease is rare in
patients with HHT, but such individuals should receive
lifetime surveillance for disease progression and device fail-
ure. The optimal treatment of aortic aneurysms in this
patient population remains to be defined, and future cases
should be reported.
We thank Dr E. William St. Clair, MD, for his involve-
ment in the care of this patient and for his critical review of
the manuscript.REFERENCES
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